BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...

Under the agreement, Biosion will receive over $40 million cash as an upfront license fee and reimbursement for certain development costs and drug product materials. Biosion said it will receive 19.9% ...

In a report released yesterday, Christopher Raymond from Piper Sandler upgraded Aclaris Therapeutics (ACRS – Research Report) to a Buy, with a ...

Leerink upgraded Aclaris Therapeutics (ACRS) to Outperform from Market Perform with a price target of $7, up from $2, representing over 120% ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Aclaris Therapeutics has entered an exclusive licensing deal with Biosion for two antibodies, BSI-045B for atopic dermatitis ...

Fintel reports that on November 19, 2024, BTIG upgraded their outlook for Aclaris Therapeutics (NasdaqGS:ACRS) from Neutral ...

Jefferies upgraded Aclaris Therapeutics (ACRS) to Buy from Hold with a price target of $7, up from $2. BSI-045B is the first ...

Aclaris Therapeutics (NASDAQ: ACRS) is making waves in the market today, with the stock showing a remarkable surge of +52.32%, climbing $1.58 to reach $4.72 at 01:46 PM EST on Tuesday, November 19, ...

Aclaris partners with Biosion for anti-TSLP programs and seeks $80M funding, Keymed Biosciences signs $626M potential deal with Ouro Medicines, ReCode receives CF Foundation funding, Quell gets $10M ...

Food - Microbial contamination - SalmonellaDistribution: Ontario See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA) ...